22 days ago
PTGX
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Analyst Ranking
Top 12%
#593 out of 5269 analysts
Average Return
+17.1%
Win Rate
52%43 out of 83
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +520.24% | $8.50 | $52.72 | 2025-10-14 - 2026-03-31 | Strong Buy |
Verastem IncVSTM | +229.72% | $2.49 | $8.21 | 2024-08-12 - 2025-08-12 | Strong Buy |
Terns Pharmaceuticals IncTERN | +202.47% | $17.43 | $52.72 | 2025-11-03 - 2026-03-31 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-27 - 2024-06-27 | Strong Buy |
Mbx Biosciences IncMBX | +130.25% | $13.95 | $32.12 | 2025-10-14 - 2026-05-06 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
2 months ago
SEPN
2 months ago
SRRK
3 months ago
CYTK
4 months ago
PTGX
5 months ago
KYMR
5 months ago
KYMR
6 months ago
MDGL
a year ago
LLY
a year ago
PFE
a year ago
EWTX
a year ago
SRRK
2 years ago
LLY
2 years ago
LLY
2 years ago
LLY
2 years ago
KYMR
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Protagonist Therapeutics IncPTGX | 5 | Strong Buy | $121.00 | +16.38% | Maintains | 22 days ago |
Biogen IncBIIB | 7 | Hold | $189.00 | -0.88% | Maintains | 24 days ago |
Terns Pharmaceuticals IncTERN | 5 | Hold | $53.00 | +0.09% | Downgrades | a month ago |
Inventiva SaIVA | 1 | Strong Buy | $13.00 | +140.74% | Initiates Coverage On | 2 months ago |
Septerna IncSEPN | 2 | Strong Buy | $35.00 | +41.64% | Maintains | 2 months ago |
Scholar Rock Holding CorpSRRK | 6 | Strong Buy | $55.00 | +16.75% | Maintains | 2 months ago |
Cytokinetics IncCYTK | 5 | Strong Buy | $92.00 | +22.93% | Maintains | 3 months ago |
Kymera Therapeutics IncKYMR | 6 | Strong Buy | $116.00 | +34.48% | Maintains | 5 months ago |
Madrigal Pharmaceuticals IncMDGL | 2 | Strong Buy | $640.00 | +18.58% | Maintains | 6 months ago |
Incyte CorpINCY | 12 | Hold | $93.00 | -6.86% | Reiterates | 6 months ago |
Viatris IncVTRS | 1 | Strong Buy | $15.00 | -5.96% | Initiates Coverage On | 7 months ago |
Mbx Biosciences IncMBX | 1 | Strong Buy | $50.00 | +55.67% | Initiates Coverage On | 7 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Strong Buy | $812.00 | +12.61% | Maintains | 9 months ago |
Arvinas IncARVN | 1 | Hold | $11.00 | N/A | Downgrades | a year ago |
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | N/A | Maintains | a year ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $1,038.00 | N/A | Maintains | a year ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | N/A | Maintains | a year ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | N/A | Maintains | a year ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | N/A | Maintains | a year ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | N/A | Upgrades | 2 years ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Affimed NvAFMDQ | 2 | Strong Buy | $60.00 | N/A | Maintains | 3 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 3 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.